NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE
Real World Evidence Study Showed use of Prolia Reduced Fracture Risk in Postmenopausal Women With Osteoporosis Versus Alendronate Treatment Longer Duration of Treatment With Prolia Was Associated... | May 8, 2023
Source: marketscreener.com